# Glaucoma Agents

## Length of Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindications to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Additional Criteria
### Step Therapy

Step Therapy Approval Criteria

1.  For a product requiring step therapy, there must have been inadequate clinical response to preferred alternatives for glaucoma, including a trial of no less than **30 days** of at least **one** preferred product
2.  For a non-preferred agent for glaucoma, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days each** of at least **two** preferred or step therapy products

## Formulary

Ophthalmic Agents: Glaucoma Agents

| PREFERRED            | NON-PREFERRED     |
|----------------------|-------------------|
| Alphagan P 0.1% ST   | Apraclonidine     |
| Alphagan P 0.15% BvG | Betoptic S        |
| Azopt BvG ST         | Bimatoprost       |
| Betaxolol            | Brimonidine 0.15% |
| Brimonidine 0.2%     | Brinzolamide      |
| Carteolol            | Iopidine          |
| Combigan BvG ST      | Istalol           |
| Dorzolamide          | Lumigan           |
| Dorzolamide/Timolol  | Travoprost        |
| Latanaprost          | Vyzulta           |
| Levobunolol          | Xelpros           |
| Metipranolol         | Zioptan           |
| Rhopressa            |                   |
| Rocklatan            |                   |
| Simbrinza            |                   |
| Timolol              |                   |
| Travatan Z BvG ST    |                   |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=84)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220701_UPDL_FINAL.pdf#page=28)